0000000000466811

AUTHOR

Susan Groshen

showing 2 related works from this author

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan

2015

SummaryProlonged fasting (PF) promotes stress resistance, but its effects on longevity are poorly understood. We show that alternating PF and nutrient-rich medium extended yeast lifespan independently of established pro-longevity genes. In mice, 4 days of a diet that mimics fasting (FMD), developed to minimize the burden of PF, decreased the size of multiple organs/systems, an effect followed upon re-feeding by an elevated number of progenitor and stem cells and regeneration. Bi-monthly FMD cycles started at middle age extended longevity, lowered visceral fat, reduced cancer incidence and skin lesions, rejuvenated the immune system, and retarded bone mineral density loss. In old mice, FMD c…

MaleAbdominal Fat; Adult; Aged; Aging; Animals; Body Weight; Cardiovascular Diseases; Diet; Female; Humans; Male; Mice; Mice Inbred C57BL; Middle Aged; Neoplasms; Neurogenesis; Pilot Projects; Psychomotor Performance; Regeneration; Saccharomyces cerevisiae; Young Adult; Cognition; Fasting; LongevityAgingPhysiologyPilot ProjectsMiceCognitionNeoplasmsCardiovascular DiseaseSettore MED/49 - Scienze Tecniche Dietetiche Applicatemedia_common2. Zero hungerNeurogenesisLongevityFastingMiddle Aged3. Good healthCardiovascular DiseasesFemaleStem cellHumanAdultmedicine.medical_specialtyNeurogenesismedia_common.quotation_subjectLongevityAbdominal FatSaccharomyces cerevisiaeBiologyArticleYoung AdultImmune systemInternal medicineDiabetes mellitusmedicineAnimalsHumansRegenerationPilot ProjectAdverse effectCell Biology; Molecular Biology; PhysiologyMolecular BiologyAgedAnimalBody WeightCell Biologymedicine.diseaseMiddle ageDietMice Inbred C57BLEndocrinologyCancer cellNeoplasmNeurogenesiPsychomotor Performance
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct